Compensation award — excluded from discretionary-purchase analysis.
Traded Dec 23, 2025 · Filed Dec 30, 2025
The money chief of Roivant Sciences sold $5.84M of Roivant Sciences shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$5,837,000
Shares × reported transaction price
43 days after results of Nov 10, 2025, 45 days before results of Feb 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +1.3% | +1.1% | +0.2% |
| 30 days | −0.4% | +1.5% | −1.8% |
| 90 days | +27.6% | −4.6% | +32.3% |
| 180 days | +60.0% | +8.7% | +51.4% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Routine share withholding; mechanical by default.
Compensation award — excluded from discretionary-purchase analysis.